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Introduction: Correct mediastinal staging is critical for determina-
tion of the most appropriate management strategy in patients with 
non–small-cell lung cancer (NSCLC). The purpose of this study was 
to compare the diagnostic performance of endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-TBNA) with that of 
mediastinoscopy in patients with NSCLC.
Methods: A prospective trial was conducted in a tertiary referral 
center in Korea. Patients with histologically proven NSCLC and 
suspicion for N1, N2, or N3 metastasis were enrolled. Each patient 
underwent EBUS-TBNA followed by mediastinoscopy. Surgical 
resection and complete lymph node dissection were conducted in 
patients for whom no evidence of mediastinal metastasis was appar-
ent after mediastinoscopy.
Results: In total, 138 patients underwent EBUS-TBNA and 127 
completed both EBUS-TBNA and mediastinoscopy. N2/N3 disease 
was confirmed in 59.1% of the patients. The diagnostic sensitivity, 
specificity, accuracy, positive predictive value, and negative predic-
tive value (NPV) of EBUS-TBNA on a per-person analysis were 
88.0%, 100%, 92.9%, 100%, and 85.2%, respectively. The diagnostic 
sensitivity, specificity, accuracy, positive predictive value, and NPV 
of mediastinoscopy on a per-person analysis were 81.3%, 100%, 
89.0%, 100%, and 78.8%, respectively. Significant differences in the 
sensitivity, accuracy, and NPV were evident between EBUS-TBNA 
and mediastinoscopy (p < 0.005).
Conclusions: EBUS-TBNA was superior to mediastinoscopy in 
terms of its diagnostic performance for mediastinal staging of cN1–3 
NSCLC. Because EBUS-TBNA is both less invasive and affords 
superior diagnostic sensitivity, it should be the first-line procedure 
performed in patients with NSCLC.
Key Words: Carcinoma, non–small-cell lung, ultrasonography, 
mediastinoscopy, neoplasm staging, mediastinum
(J Thorac Oncol. 2015;10: 331–337)
Primary lung cancer is the most frequent cause of death due to cancer worldwide.1,2 Accurate mediastinal staging 
is critical for selection of the most appropriate management 
strategy and evaluation of the prognosis in patients with non–
small-cell lung cancer (NSCLC) who are potential candidates 
for curative resection.
Many noninvasive imaging studies using chest computed 
tomography (CT) and positron emission tomography (PET)/
CT have been conducted. The pooled diagnostic sensitivity and 
specificity of chest CT and PET/CT were 55% and 81%, and 
62% and 90%, respectively.3 Noninvasive mediastinal nodal 
staging is not satisfactory because of its high false-positive and 
false-negative rates.3 Abnormal findings on noninvasive testing 
must be examined by biopsy for accurate staging.3,4
Mediastinoscopy is performed under general anesthesia 
and allows the subcarinal and paratracheal lymph node stations 
to be accessed. Although mediastinoscopy is considered to be the 
diagnostic standard, the pooled sensitivity and negative predictive 
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values of traditional and video-assisted mediastinoscopy (VAM) 
for mediastinal staging were only 78% and 91%, and 89% and 
92%, respectively.3 The technique is invasive and the morbidity 
and mortality rates are 2% and 0.08%, respectively.3,5
Endobronchial ultrasound-guided transbronchial nee-
dle aspiration (EBUS-TBNA) is a less invasive intervention 
permitting mediastinal nodal staging under direct endobron-
chial ultrasonic guidance.6–10 In earlier systemic reviews and 
meta-analyses, the diagnostic sensitivities of EBUS-TBNA 
ranged from 88% to 93%, comparable to those of mediasti-
noscopy.3,11,12 Although such data are promising, only two 
prospective studies have directly compared EBUS-TBNA 
and mediastinoscopy.13,14 EBUS-TBNA was superior to medi-
astinoscopy in terms of sensitivity in one study (87% versus 
68%),14 but the two methods were of similar diagnostic sen-
sitivity in the other (81% versus 79%).13 However, the cited 
works may not reflect the real-life clinical utility of EBUS-
TBNA because the procedure was performed under general 
anesthesia. The objective of this study was to compare the 
diagnostic performance of EBUS-TBNA under conscious 
sedation and local anesthesia with that of mediastinoscopy 
used to identify N2/N3 metastasis in patients with NSCLC.
PATIENTS AND METHODS
Study Patients
This was a single-center prospective trial involving 
patients with potentially resectable NSCLC. This study was 
conducted in accordance with the amended Declaration 
of Helsinki. The study was approved by the Institutional 
Review Board of the Samsung Medical Center (IRB No. 
2009-08-053) and was registered at www.clinicaltrials.gov 
(NCT01079520). Written informed consent was obtained 
from each patient. Diagnostic evaluation included a conven-
tional workup, bronchoscopy, CT, and integrated whole-body 
18F-fluorodeoxyglucose (FDG) PET/CT scanning.
A patient was included if the guidelines indicated that 
mediastinal nodal sampling was appropriate.4,15 The inclusion 
criteria were as follows: (1) Histologically proven NSCLC; (2) 
a suspicion of N2 or N3 lymph node metastasis on chest CT or 
PET/CT scans [at least one of three criteria had to be met, and 
these were: (a) enlarged (short-axis diameter 1 cm or more) medi-
astinal node(s), (b) FDG uptake by mediastinal node(s), and/or (c) 
FDG uptake by N1 node(s)]; and (3) the subject was a candidate 
for curative surgery. The exclusion criteria were as follows: (1) 
distant metastasis, (2) inoperable T4 disease, (3) supraclavicular 
lymph node metastasis, (4) a history of prior therapy for lung can-
cer, (5) the presence of contraindication(s) for bronchoscopy, (6) 
uncorrected coagulopathy, (7) another concurrent malignancy, 
and/or (8) any suspicious mediastinal node metastasis inacces-
sible by EBUS-TBNA or mediastinoscopy (i.e., the para-aortic, 
aortopulmonary window, or para-esophageal lymph nodes).
Study Design
Each patient underwent EBUS-TBNA followed by 
mediastinoscopy. Thoracic surgeons and pathologists were 
blinded to the EBUS-TBNA data, which were used for research 
purposes and were disclosed only after the mediastinoscopy. 
However, if N3 disease was confirmed by EBUS-TBNA at 
any nodal station examined (the contralateral hilar, contra-
lateral interlobar, or highest mediastinal lymph nodes) that 
was inaccessible by mediastinoscopy, the latter procedure was 
cancelled and the EBUS-TBNA results were reported because 
performance of mediastinoscopy was not ethically justifiable. 
Mediastinoscopy was performed within 3 weeks of EBUS-
TBNA. The treatment decision was made according to the 
result of mediastinoscopy in each patient.
Endobronchial Ultrasound-Guided 
Transbronchial Needle Aspiration
EBUS-TBNA and biopsies were conducted using a convex 
probe-EBUS bronchoscope (BF-UC260F-OL8; Olympus, Tokyo, 
Japan) and a 22-gauge needle (NA-201SX-4022; Olympus).6,16 
The interventions were conducted with local anesthesia through 
nebulization with lidocaine and conscious sedation using mid-
azolam.16 Each visible station was sampled systematically.17 If a 
station had multiple lymph nodes on EBUS, we chose the lymph 
node based on the size and18F-FDG uptake. Core tissue was placed 
on filter paper to absorb excess blood, fixed in 10% (v/v) formalin, 
and the tissue coagulum clot was sent for histological examina-
tion.16,18,19 Aspirates were discharged onto slides, smeared, fixed 
in 95% (v/v) ethanol, and sent for cytological examination. When 
possible, we conducted three passes per node. When core tissue 
was obtained, at least two passes were conducted when possible. 
Rapid on-site cytopathological evaluation was not available. All 
interventions were conducted by two bronchoscopists (U.S.W. and 
L.K.J.) who had experiences with more than 300 cases of EBUS-
TBNA before study initiation. All lymph nodes were classified 
in terms of the International Association for the Study of Lung 
Cancer lymph node map.20
Mediastinoscopy
Traditional cervical mediastinoscopy and VAM were 
performed by experienced thoracic surgeons (K.H.K., C.Y.S., 
S.Y.M., and K.J.) who had experiences with more than 
1000 cases of mediastinoscopy before study initiation.21,22 
Mediastinoscopic examination was performed to evaluate 
lymph nodes in stations 2R, 2L, 4R, 4L, and 7. Each nodal 
station was biopsied regardless of nodal appearance or size. 
All specimens collected by mediastinoscopy were promptly 
transported to a pathologist located in the operating theater. 
That pathologist examined frozen sections, and surgery did 
not proceed until the results were received.
Surgical Resection
If N2/N3 disease was not noted in frozen sections of 
mediastinoscopy biopsies, patients immediately underwent 
lung resection surgery with systematic mediastinal lymph 
node dissection, which included resection of each node at sta-
tions 2R, 4R, 7, 8, and 9 for right-sided tumors and at stations 
4L, 5, 6, 7, 8, and 9 for left-sided tumors.
Diagnostic Standards
The positive and negative diagnostic standards were 
cytopathological confirmation of the presence or absence of 
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malignancy, respectively, using all available tissue-sampling 
methods (EBUS-TBNA, mediastinoscopy, or mediastinal 
lymph node dissection).
Statistical Analysis
All data are presented as medians (with ranges) or num-
bers (with % values). The diagnostic sensitivity, specificity, 
accuracy, positive predictive value (PPV), and negative predic-
tive value (NPV) of EBUS-TBNA and mediastinoscopy were 
calculated on a per-person basis using standard definitions.
The primary end point of the study was to demon-
strate that EBUS-TBNA was not inferior to mediastinos-
copy in the detection of N2 or N3 metastases (sensitivity). 
Secondary end points were to compare the specificity, accu-
racy, PPV, and NPV of the two diagnostic methods. The null 
hypothesis was that the sensitivity of EBUS-TBNA (P
E
) 
would be lower than that of mediastinoscopy (P
M
) by a non-
inferiority margin of 10%, and the alternative hypothesis 
was that P
E
 would be possibly higher than P
M
 by a superior-
ity margin of 5%. Assuming the presence of 20% discordant 
pairs, the noninferiority test for the null hypothesis with a 
one-sided alpha of 5% required 75 patients with mediastinal 
nodal metastasis to detect the alternative hypothesis with 
a 90% power. Assuming a 60% prevalence of mediastinal 
nodal metastasis in a prospective cohort formed using simi-
lar inclusion criteria,23 and a 10% dropout, a sample size of 
139 patients was required.
Per-patient analyses of the two diagnostic methods in 
terms of sensitivity, specificity, and accuracy were evaluated 
using the asymptotic McNemar test. The comparison of PPV 
and NPV between two diagnostic methods was conducted 
using a weighted least squares test.24 The diagnostic sensitiv-
ity of each nodal station was evaluated using the asymptotic 
McNemar test. Comparisons between the performance of tra-
ditional mediastinoscopy and VAM were performed using the 
two-sample t test. Statistical analyses were conducted using 
IBM SPSS Statistics version 20.0 (SPSS Inc., Chicago, IL) 
and R version 2.15.2 (http://www.r-project.org).
RESULTS
Study Algorithm
Between March 2010 and May 2012, 250 consecu-
tive patients with resectable histology-proven NSCLC were 
assessed for study eligibility, and 112 were excluded (Fig. 1). 
One hundred and thirty-eight patients underwent initial 
EBUS-TBNA. Of these, eight dropped out, refusing to partici-
pate further. Of 25 patients in whom the contralateral hilar or 
interlobar lymph nodes had been examined by EBUS-TBNA 
(n = 138), N3 disease was confirmed in three, who therefore 
did not undergo mediastinoscopy. Among these three patients, 
two had additional N2 metastasis and one had additional N3 
metastasis. Of 127 patients who underwent mediastinoscopy, 
58 yielded positive results on examination of frozen sections 
of mediastinoscopy tissue.
Of 69 patients who yielded negative results upon 
examination of frozen sections after mediastinoscopy, 66 
underwent lung resection surgery and systematic lymph 
node dissection, and N2/N3 metastasis was confirmed in 
nine (eight by lymph node dissection and one by both for-
mal histopathological examination after mediastinoscopy 
and lymph node dissection). In three patients who did not 
yield positive results on examination of frozen sections 
of mediastinoscopy tissue, but who did not undergo lung 
resection surgery, malignancy was confirmed in two by for-
mal histopathological examination of mediastinoscopy tis-
sue and in one through EBUS-TBNA. Therefore, N2 or N3 
involvement was solely confirmed by EBUS-TBNA, medi-
astinoscopy, and mediastinal lymph node dissection in six, 
four, and three patients, respectively. The trial ended when 
75 patients were identified as having N2 or N3 metastasis by 
EBUS-TBNA, mediastinoscopy, or mediastinal lymph node 
dissection.
Patient Demographics and Lymph 
Nodal Stations Examined
Table 1 shows the demographic characteristics of the 
subjects. The median age was 62 years and 84.8% were male. 
The most frequent clinical T stage was T2a (34.1%), and the 
most common clinical N stage was N2 (68.1%), followed by 
N3 (17.4%) and N1 (14.5%). The most common final histo-
pathology was squamous cell carcinoma (54.3%), followed 
by adenocarcinoma (39.9%). The median numbers of lymph 
nodal stations examined by EBUS-TBNA and mediastinos-
copy were both three.
Table 2 shows the nodal stations examined. A total of 
524 lymph nodes were examined using at least one of the 
three methods. Totals of 376, 398, and 201 lymph nodes were 
examined by EBUS-TBNA (in 127 patients), mediastinos-
copy (in 127 patients), and surgical lymph node dissection 
(in 64 patients), respectively. The median short- and long-axis 
diameters of the largest lymph node in each station examined 
were 9 and 14 mm, respectively. Core tissues were obtained in 
97.1% of the nodes examined by EBUS-TBNA.
Analysis of Diagnostic Performance
The prevalence of N2/N3 metastasis in the cohort 
included in diagnostic performance analysis was 59.1% (75 
out of 127). Table 3 shows the diagnostic performances of 
EBUS-TBNA and mediastinoscopy based on a per-person 
analysis. The sensitivity, specificity, accuracy, PPV, and NPV 
of EBUS-TBNA were 88.0% (95% confidence interval [CI] 
80.6–95.4%), 100% (95% CI 100–100%), 92.9% (95% CI 
88.5–97.4%), 100% (95% CI 100–100%), and 85.2% (95% 
CI 76.3–94.1%), respectively. The sensitivity, specificity, 
accuracy, PPV, and NPV of mediastinoscopy were 81.3% 
(95% CI 72.5–90.2%), 100% (95% CI 100–100%), 89.0% 
(95% CI 83.5–94.4%), 100% (95% CI 100–100%), and 
78.8% (95% CI 68.9–88.7%), respectively. Significant dif-
ferences in sensitivity (p = 0.0039), accuracy (p = 0.0001), 
and NPV (p = 0.0018) were evident between EBUS-TBNA 
and mediastinoscopy.
Subgroup Analysis
Table 4 shows the diagnostic sensitivities of the individ-
ual lymph nodal stations afforded by the two tests. In station 
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4L, a significant difference in diagnostic sensitivity was evi-
dent between EBUS-TBNA (81.0%; 95% CI 64.2–97.7%) and 
mediastinoscopy (52.4%, 95% CI 31.0–73.7%) (p = 0.0270).
There was no significant difference in the diagnostic sen-
sitivity of traditional mediastinoscopy (63.6%; 95% CI 43.5–
83.7%) and VAM 83.0%; 95% CI 72.9–93.1%) (p = 0.0679).
Adverse Events
There were no mortalities and major events related 
to EBUS-TBNA or mediastinoscopy. Minor events during 
EBUS-TBNA included minor bleeding (n = 1) and transient 
hypoxemia (n = 1). Minor event during mediastinoscopy 
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DISCUSSION
This prospective study clearly demonstrated that the 
diagnostic sensitivity, accuracy, and NPV of EBUS-TBNA 
were higher than those of mediastinoscopy for the mediastinal 
nodal staging of cN1-3 NSCLC. Only two prospective studies 
have directly compared EBUS-TBNA and mediastinoscopy.13,14 
However, these studies may not reflect the real-life utility of 
EBUS-TBNA because the procedure was performed at the time 
of mediastinoscopy under general anesthesia in some or all study 
subjects.13,14 Further, the two cited studies may not have been 
adequately powered to allow for a fair comparison of EBUS-
TBNA with mediastinoscopy. No formal sample size calculation 
was conducted in either study.13,14 The strengths of our study are 
that EBUS-TBNA was compared with mediastinoscopy after 
the formal sample size calculation and that all EBUS-TBNA 
procedures were conducted under conscious sedation.
Although correct mediastinal staging is vital for the man-
agement of NSCLC, the optimal approach to invasive mediasti-
nal staging remains controversial. Recent American College of 
Chest Physicians and European Society of Thoracic Surgeons 
guidelines have recommended a needle-based technique, such 
as endoscopic ultrasound fine needle aspiration (EUS-FNA) 
or EBUS-TBNA, over mediastinoscopy as the optimal first 
test.3,25 This recommendation was based on systemic reviews 
and meta-analyses of the diagnostic performances of EBUS-
TBNA and mediastinoscopy. The pooled diagnostic sensitivi-
ties of EBUS-TBNA ranged from 88% to 93%, comparable to 
those of traditional mediastinoscopy (78%) or VAM (89%).3,11,12 
The superiority of a combined approach of EBUS-TBNA and 
EUS-FNA over either procedure alone was reported previ-
ously.26–29 A staging strategy combining endosonography (EUS-
FNA or EBUS-TBNA) and surgery, compared with surgery 
alone, afforded higher sensitivity in detecting mediastinal nodal 
metastases, and fewer futile thoracotomies resulted.27
Several factors contributed to the superior sensitivity 
of EBUS-TBNA. First, EBUS-TBNA allows for visualization 
and localization of a target lymph node using real-time ultra-
sonic guidance even when the target is deeply buried or very 
close to a vessel. In this study, mediastinoscopy was of lower 
sensitivity (52.4%) when used to diagnose metastasis in the 
TABLE 1.  Clinical Characteristics of the Patients (n = 138)
Characteristic
No. (%) or  
Median (Range)
Age (years) 62 (34–76)
Male gender 117 (84.8%)
Smoker/nonsmoker 110 (79.7)/28 (20.3)
Pack-years 35 (0–125)
Tumor stage by PET/CT 138 (100)
  T1a 7 (5.1)
  T1b 19 (13.8)
  T2a 47 (34.1)
  T2b 26 (18.8)
  T3 38 (27.5)
  T4 1 (0.7)
Nodal stage by PET/CT 138 (100)
  N1 20 (14.5)
  N2 94 (68.1)
  N3 24 (17.4)
Final histopathology 138 (100)
  Squamous cell carcinoma 75 (54.3)
  Adenocarcinoma 55 (39.9)
  NSCLC NOS 6 (4.3)
  LCNEC 1 (0.7)
  Pleomorphic carcinoma 1 (0.7)
Number of nodal stations examined
  EBUS-TBNA (n = 138) 3 (1–6)
  Mediastinoscopy (n = 127) 3 (1–6)
  Mediastinal lymph node dissection (n = 64) 3 (1–6)
Time interval between EBUS-TBNA and 
mediastinoscopy, days (n = 127)
6 (0–19)
Number of passes per each nodal station during  
EBUS-TBNA
2 (1–5)
Type of mediastinoscopy 127 (100)
  Traditional 42 (33.1)
  Video-assisted 85 (66.9)
Lung resection surgery 55 (100)
  Lobectomy 47 (85.5)
  Bilobectomy 8 (14.5)
  Pneumonectomy 9 (16.4)
  Wedge resection 1 (1.8)
EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; 
LCNEC, large-cell neuroendocrine carcinoma; NSCLC NOS, non–small-cell lung 









1R 3 2 1 5
2L 5 9 0 12
2R 43 48 16 67
3A 0 0 11 11
3P 0 0 1 1
4L 89 98 14 111
4R 114 121 38 125
5 0 0 20 21
6 0 0 6 6
7 122 120 56 126
8 0 0 4 4
9L 0 0 13 14
9R 0 0 21 21
Total 376 398 201 524
Short-axis  
diameter of the  
largest lymph node  
in each nodal  
station (mm)
9 (3–30) 10 (3–30) 10 (3–28) 9 (3–30)
aMediastinal lymph node dissection was conducted in 64 patients.
EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration.
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4L lymph node than was EBUS-TBNA (81.0%). It is difficult 
to use mediastinoscopy to access the deeply located 4L lymph 
node, which is close to the ascending aorta, the pulmonary 
artery, and the recurrent laryngeal nerve. There was a ten-
dency for lower diagnostic sensitivity of the subcarinal lymph 
node by mediastinoscopy (75.0% versus 82.5%), which could 
be partly due to the fact that with mediastinoscopy, it was 
not possible to access the posteriorly located deep subcari-
nal lymph node. Second, during EBUS-TBNA, we performed 
systematic sampling of representative nodes in all visible sta-
tions rather than selective sampling of just one or two nodal 
stations. The accuracy of mediastinal nodal staging depends 
not only on the test used but also on the thoroughness with 
which the procedure is performed.17 The median number and 
short-axis diameter of the nodes examined by EBUS-TBNA 
were three and 9 mm, respectively, comparable to those of 
nodes examined by mediastinoscopy. Histologic cores were 
obtained in 97.1% of the nodes examined by EBUS-TBNA. 
The high success rate of EBUS-TBNA biopsy in this study 
suggests that it provides high diagnostic performance even 
without the use of rapid on-site cytopathological evaluation. 
Finally, EBUS-TBNA can also detect N3 disease in contra-
lateral hilar or interlobar lymph nodes that are inaccessible 
using mediastinoscopy. Twenty-five of 138 patients who 
underwent EBUS-TBNA were evaluated in terms of contra-
lateral hilar or interlobar lymph node metastasis; N3 disease 
was confirmed in three.
In this study, there was a tendency of higher diagnostic 
sensitivity of VAM (83.0%) compared with that of traditional 
mediastinoscopy (63.6%), but it was not statistically signifi-
cant. Potential advantages of VAM over traditional mediasti-
noscopy include enhanced views on the monitor and a more 
comfortable surgical working environment.30 The total num-
ber of dissected nodes was higher in the VAM group than in 
the traditional mediastinoscopy group in the previous study.30
A limitation of this study is that all work was conducted 
in a single tertiary referral center, which potentially restricts the 
applicability of our findings. It is also possible that less-expe-
rienced groups may be unable to use EBUS-TBNA as effec-
tively as did we, and the sensitivity of the technique would thus 
be lower in other hands. Another limitation is that the median 
number of mediastinal nodal stations examined by lymph node 
dissection was relatively small (n = 3), which might be asso-
ciated with high proportion of VAM (66.9%). The number of 
remaining lymph nodes after VAM was smaller than that after 
traditional mediastinoscopy because VAM enabled complete 
removal of more lymph nodes.30 Finally, although recent guide-
lines recommended invasive nodal staging of a centrally located 
tumor with N0 disease, we did not include these patients.3,25 
Thus, our data regarding cN1–3 should not be extrapolated to 
central tumors with N0 disease. We also excluded the patients 
with histologically not proven NSCLC.
In conclusion, EBUS-TBNA was superior to mediasti-
noscopy in terms of its diagnostic performance for mediastinal 
staging of cN1-3 NSCLC. Because EBUS-TBNA is less inva-
sive and offers superior diagnostic sensitivity, this should be 
the first-line procedure performed on patients with NSCLC.
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